Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

Albert Bourla, the CEO of pharmaceutical company Pfizer ($PFE), plans to meet with activist investor Starboard Value in ...

A federal judge ordered the tech giant to let rival app stores onto its Android smartphone platform, adding to its growing ...